BioPharmSignal logoBioPharmSignal

Biotech News

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

TELA Bio (TELA)TELA BioCommercial

Company to reduce annual operating expenses by $17.0 million or 18% as part of broader efficiency program MALVERN, Pa., Aug. 31, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (“TELA Bio” or the “Company”), a commercial-stage medical technology company focused on providing innovative soft-tissue

Related news

TELATELA Bio2026-08-04 11:00 EST

TELA Bio Announces Appointment of Heather Getz as Chief Executive Officer and Director

TELATELA Bio2026-11-06 21:05 EST

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

View all latest news

TELA Bio

Soft-Tissue Reconstruction Company TELA Bio develops medical devices for hernia repair, abdominal-wall reconstruction, and plastic and reconstructive surgery. Reinforced Tissue Matrices The OviTex portfolio combines biologic tissue with polymer reinforcement to provide strength while supporting tissue remodeling. Commercial Surgical...

Recent company news

TELATELA Bio2026-11-06 21:05 EST

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TELATELA Bio2026-10-27 20:05 EST

TELA Bio to Announce Third Quarter 2026 Financial Results

TELATELA Bio2026-10-05 11:59 EST

TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement

TELATELA Bio2026-08-31 11:00 EST

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

TELATELA Bio2026-08-10 20:05 EST

TELA Bio Reports Second Quarter 2026 Financial Results

Stock data

Close
0.78 USD
Market cap
40.74M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States